Literature DB >> 24105604

A note from history: Landmarks in history of cancer, Part 6.

Steven I Hajdu1, Manjunath Vadmal.   

Abstract

In the 3 decades from 1940 to 1970, the United States became the nucleus for research, diagnosis, and treatment of cancer. The discovery of anticancer drugs, and the clinical demonstration that chemotherapy and radiation can cure cancer and have the ability to prevent recurrence of cancer, were incontrovertibly the most remarkable groundbreaking events. Consequently, the trend of less surgery and more multimodality therapy began. The introduction of radioautography, mammography, ultrasonography, computed tomography, Papanicolaou smear, and other novel laboratory tests furthered early detection of cancer and refined accurate diagnosis. The unequivocal linking of lung cancer to cigarette smoking made medical history. The delineation of the potential role of oncogenes adduced new thoughts about oncogenesis and cancer prevention, and pathologists finalized the classification and nosology of tumors. Finally, it is worth noting that although more advances were made in the detection, diagnosis, and treatment of cancers than any other period in history, the overall mortality rate of patients with cancer remained high and unchanged.
© 2013 American Cancer Society.

Entities:  

Keywords:  history of cancer; history of cancer epidemiology and cancer institutions; history of cancer research; history of cytopathology; history of diagnostic radiology; history of immunology; history of medical oncology; history of radiation therapy; history of surgical oncology; history of surgical pathology

Mesh:

Year:  2013        PMID: 24105604     DOI: 10.1002/cncr.28319

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Fibromyxoma of the Jaw: Case Report and Review of the Literature.

Authors:  Thabet Alhousami; Amarpreet Sabharwal; Shivane Gupta; Alfredo Aguirre; Etern Park; Jill M Kramer
Journal:  Head Neck Pathol       Date:  2017-05-16

Review 2.  Solid Tumors and Kinase Inhibition: Management and Therapy Efficacy Evolution.

Authors:  Flávia Melo Cunha de Pinho Pessoa; Caio Bezerra Machado; Emerson Lucena da Silva; Laudreísa da Costa Pantoja; Rodrigo Monteiro Ribeiro; Maria Elisabete Amaral de Moraes; Manoel Odorico de Moraes Filho; Raquel Carvalho Montenegro; André Salim Khayat; Caroline Aquino Moreira-Nunes
Journal:  Int J Mol Sci       Date:  2022-03-30       Impact factor: 5.923

Review 3.  Cancer Stem Cells (CSCs), Circulating Tumor Cells (CTCs) and Their Interplay with Cancer Associated Fibroblasts (CAFs): A New World of Targets and Treatments.

Authors:  Beatrice Aramini; Valentina Masciale; Chiara Arienti; Massimo Dominici; Franco Stella; Giovanni Martinelli; Francesco Fabbri
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

4.  Antibody Therapeutics in Oncology.

Authors:  Erik D Wold; Vaughn V Smider; Brunhilde H Felding
Journal:  Immunotherapy (Los Angel)       Date:  2016-02-01

Review 5.  Current Developments of N-Heterocyclic Carbene Au(I)/Au(III) Complexes toward Cancer Treatment.

Authors:  Alexia Tialiou; Jiamin Chin; Bernhard K Keppler; Michael R Reithofer
Journal:  Biomedicines       Date:  2022-06-15

Review 6.  Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium.

Authors:  Luca Falzone; Salvatore Salomone; Massimo Libra
Journal:  Front Pharmacol       Date:  2018-11-13       Impact factor: 5.810

Review 7.  Colorectal Cancer Screening: Impact of COVID-19 Pandemic and Possible Consequences.

Authors:  Isabelle Harber; Dania Zeidan; Muhammad N Aslam
Journal:  Life (Basel)       Date:  2021-11-26

8.  Targeting and pharmacology of an anti-IL13Rα2 antibody and antibody-drug conjugate in a melanoma xenograft model.

Authors:  Parul Gupta; Ziyue Karen Jiang; Bing Yang; Lisa Manzuk; Edward Rosfjord; Johnny Yao; Luanna Lemon; Kavon Noorbehesht; John David; Sujiet Puthenveetil; Jeffrey M Casavant; Elwira Muszynska; Fengping Li; Mauricio Leal; Puja Sapra; Anand Giddabasappa
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.